Reshma Rangwala Biography and Net Worth

Chief Medical Officer & Head of Research of Karyopharm Therapeutics

Dr. Rangwala is the Chief Medical Officer and Head of Research at Karyopharm. She oversees all aspects of research, from discovery and early development through regulatory approval. Dr. Rangwala brings more than a decade of experience in oncology and drug development to her role at Karyopharm. She was most recently the Chief Medical Officer at Aravive, where she led the clinical development of batiraxcept across multiple tumor types. Prior to Aravive, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparations. Prior to Genmab, she served as Executive Clinical Director at Merck & Co., where she was involved in the clinical development of KEYTRUDA in non-small cell lung cancer and gynecologic malignancies. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. She completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, MO and her medical oncology fellowship at the Hospital of the University of Pennsylvania.

What is Reshma Rangwala's net worth?: The estimated net worth of Reshma Rangwala is at least $536.44 thousand as of April 21st, 2026. Dr. Rangwala owns 56,290 shares of Karyopharm Therapeutics stock worth more than $536,444 as of July 16th. This net worth estimate does not reflect any other investments that Dr. Rangwala may own. Learn More about Reshma Rangwala's net worth.
How do I contact Reshma Rangwala?: The corporate mailing address for Dr. Rangwala and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Reshma Rangwala's contact information.
Has Reshma Rangwala been buying or selling shares of Karyopharm Therapeutics?: Reshma Rangwala has not been actively trading shares of Karyopharm Therapeutics during the last quarter. Most recently, Reshma Rangwala sold 449 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $8.94, for a transaction totalling $4,014.06. Following the completion of the sale, the executive vice president now directly owns 56,290 shares of the company's stock, valued at $503,232.60. Learn More on Reshma Rangwala's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Reshma Rangwala (Chief Medical Officer & Head of Research), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,958 shares worth more than $19,037.72. The most recent insider tranaction occured on April, 21st when EVP Reshma Rangwala sold 449 shares worth more than $4,014.06. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/21/2026.

Reshma Rangwala Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/21/2026	Sell	449	$8.94	$4,014.06	56,290
9/15/2025	Sell	408	$6.43	$2,623.44	29,390
4/23/2025	Sell	419	$6.17	$2,585.23	28,853
4/22/2024	Sell	452	$17.55	$7,932.60	22,862
2/29/2024	Sell	1,044	$17.55	$18,322.20	23,712
4/20/2023	Sell	451	$60.75	$27,398.25	10,548

Reshma Rangwala Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $9.53

$9.38

$9.86

50 Day Range

MA: $9.15

$7.14

$10.67

2 Week Range

Now: $9.53

$3.65

$10.99

Volume

315,583 shs

Average Volume

518,590 shs

Market Capitalization

$215.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8